Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12


The effects of DNA methylation on human psychology.

Kader F, Ghai M, Maharaj L.

Behav Brain Res. 2018 Jul 2;346:47-65. doi: 10.1016/j.bbr.2017.12.004. Epub 2017 Dec 10. Review.


The histone deacetylase inhibitor UCL67022 has potent activity in multiple myeloma and non-Hodgkin lymphoma pre-clinical models.

Maharaj L, Marson CM, Middleton BJ, Rioja AS, Perry J, Oakervee H, Cavenagh J, Joel SP, Popat R.

Br J Haematol. 2013 Oct;163(1):135-9. doi: 10.1111/bjh.12456. Epub 2013 Jul 9. No abstract available.


P110α-mediated constitutive PI3K signaling limits the efficacy of p110δ-selective inhibition in mantle cell lymphoma, particularly with multiple relapse.

Iyengar S, Clear A, Bödör C, Maharaj L, Lee A, Calaminici M, Matthews J, Iqbal S, Auer R, Gribben J, Joel S.

Blood. 2013 Mar 21;121(12):2274-84. doi: 10.1182/blood-2012-10-460832. Epub 2013 Jan 22.


Schedule dependent cytotoxicity of bortezomib and melphalan in multiple myeloma.

Popat R, Maharaj L, Oakervee H, Cavenagh J, Joel S.

Br J Haematol. 2013 Jan;160(1):111-4. doi: 10.1111/bjh.12089. Epub 2012 Oct 18. No abstract available.


Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib.

Ishii T, Seike T, Nakashima T, Juliger S, Maharaj L, Soga S, Akinaga S, Cavenagh J, Joel S, Shiotsu Y.

Blood Cancer J. 2012 Apr;2(4):e68. doi: 10.1038/bcj.2012.13. Epub 2012 Apr 27.


Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis.

Delage B, Luong P, Maharaj L, O'Riain C, Syed N, Crook T, Hatzimichael E, Papoudou-Bai A, Mitchell TJ, Whittaker SJ, Cerio R, Gribben J, Lemoine N, Bomalaski J, Li CF, Joel S, Fitzgibbon J, Chen LT, Szlosarek PW.

Cell Death Dis. 2012 Jul 5;3:e342. doi: 10.1038/cddis.2012.83.


Methylseleninic acid inhibits HDAC activity in diffuse large B-cell lymphoma cell lines.

Kassam S, Goenaga-Infante H, Maharaj L, Hiley CT, Juliger S, Joel SP.

Cancer Chemother Pharmacol. 2011 Sep;68(3):815-21. doi: 10.1007/s00280-011-1649-1. Epub 2011 Apr 26.


GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death.

Streetly MJ, Maharaj L, Joel S, Schey SA, Gribben JG, Cotter FE.

Blood. 2010 May 13;115(19):3939-48. doi: 10.1182/blood-2009-10-251660. Epub 2010 Feb 26.


In vitro antitumour and hepatotoxicity profiles of Au(I) and Ag(I) bidentate pyridyl phosphine complexes and relationships to cellular uptake.

Liu JJ, Galettis P, Farr A, Maharaj L, Samarasinha H, McGechan AC, Baguley BC, Bowen RJ, Berners-Price SJ, McKeage MJ.

J Inorg Biochem. 2008 Feb;102(2):303-10. Epub 2007 Sep 26.


The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.

Strauss SJ, Higginbottom K, Jüliger S, Maharaj L, Allen P, Schenkein D, Lister TA, Joel SP.

Cancer Res. 2007 Mar 15;67(6):2783-90.


Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity.

Strauss SJ, Maharaj L, Hoare S, Johnson PW, Radford JA, Vinnecombe S, Millard L, Rohatiner A, Boral A, Trehu E, Schenkein D, Balkwill F, Joel SP, Lister TA.

J Clin Oncol. 2006 May 1;24(13):2105-12. Epub 2006 Apr 10.


The activity of methylated and non-methylated selenium species in lymphoma cell lines and primary tumours.

Last K, Maharaj L, Perry J, Strauss S, Fitzgibbon J, Lister TA, Joel S.

Ann Oncol. 2006 May;17(5):773-9. Epub 2006 Feb 9.

Supplemental Content

Loading ...
Support Center